Similar Items: Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry
- Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
- Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema
- Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report
- Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials
- Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study)
- Subfoveal Choroidal Thickness in Clinically Significant Pseudophakic Cystoid Macular Edema: An Interocular Comparison with Contralateral Pseudophakic Eyes